SLRX
- Salarius Pharmaceuticals, Inc.
()
Overview
Company Summary
Salarius Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel oncology treatments. The company is dedicated to uncovering and creating targeted therapies to address the unmet medical needs of patients suffering from various types of cancer.
Salarius utilizes its proprietary technology platform called epigenetics to develop therapies that specifically target and modify the activity of histone modulators, which are enzymes involved in controlling gene expression. By modifying histone modulators, Salarius aims to disrupt the processes that contribute to cancer growth and progression, leading to the development of more effective and precise treatments.
One of the key therapeutic candidates being developed by Salarius is Seclidemstat. This small molecule inhibitor targets the EZH2 and LSD1 enzymes, which are known to play critical roles in the development and progression of several types of cancer, including hematologic malignancies and solid tumors. Seclidemstat has shown promising results in preclinical studies, and the company is currently advancing it through clinical trials to evaluate its safety and efficacy in treating various types of cancers.
In addition to its research and development efforts, Salarius also focuses on strategic collaborations and partnerships to further advance its pipeline of oncology therapies. By working with academic institutions, research organizations, and other pharmaceutical companies, Salarius aims to leverage external expertise and resources to accelerate the development and commercialization of its innovative treatments.
Overall, Salarius Pharmaceuticals, Inc. is dedicated to using its unique epigenetics platform to develop novel therapies that target and modify histone modulators, with the ultimate goal of improving outcomes for cancer patients.